The Outcomes of Sixty-Two Patients With Burkitt Lymphoma A Single-Center Study At King Abdulaziz Medical City Jeddah, Saudi Arabia

International Journal of Medical Science

© 2021 by SSRG - IJMS Journal

Volume 8 Issue 3

Year of Publication : 2021

Authors : Amani Ahmed

10.14445/23939117/IJMS-V8I3P101

How to Cite?

Amani Ahmed, "The Outcomes of Sixty-Two Patients With Burkitt Lymphoma A Single-Center Study At King Abdulaziz Medical City Jeddah, Saudi Arabia," SSRG International Journal of Medical Science, vol. 8,  no. 3, pp. 1-5, 2021. Crossref, https://doi.org/10.14445/23939117/IJMS-V8I3P101

Abstract:

Burkitt lymphoma (BL) is a highly aggressive curable mature B-cell non-Hodgkin lymphoma characterized by the deregulation of the c-MYC gene on chromosome 8. It has three clinical forms, of which the sporadic type is the most common. I conducted this study because the literature is deficient to Burkitt lymphoma in Saudi Arabia.
Method: a retrospective study of 62 patients treated for Burkitt lymphoma in the Princess Norah Oncology Center at King Abdulaziz Medical City in Jeddah, Saudi Arabia, between 2000 and 2017. Patient characteristics, progressive-free survival rates, and overall survival rates were assessed.
Results
The majority of patients were in the high-risk group, which was defined as the disease at an advanced stage with bone marrow and CNS involvement. The survival rates with different treatment protocols were comparable to international rates. Less intense chemotherapy, such as R-EPOCH, are good alternatives for treating Burkitt lymphoma regardless of HIV status. Elderly patients have relatively low survival rates because only around one-third are cured of the disease. Thus, more studies should be conducted on high-risk elderly patient populations

Keywords:

Burkitt, lymphoma, outcome, REPOCH, RCODOX-M

References:

[1] Costa LJ, Xavier AC, Wahlquist AE, Hill EG., Trends in survival of patients with Burkitt lymphoma/leukemia in the USA: An analysis of 3,691 cases. Blood. 121:4861,(2013).
[2] Magrath, I, Adde M, Shad A, et al., Adults and children with small non-cleaved-cell lymphoma have similar excellent outcomes when treated with the same chemotherapy regimen. J Clin Oncol, (1996) 14:925.
[3] Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood, 127(20) (2016) 2375.
[4] Hummel M, Bentinck S, Berger H, et al., A biological definition of Burkitt's lymphoma from transcriptional and genomic profiling, In Molecular Mechanisms in Malignant Lymphomas Network Project of the Deutsche Krebshilfe, N Engl J Med., 354(23) (2006) 2419.
[5] Magrath I., Epidemiology: clues to the pathogenesis of Burkitt lymphoma, Br J Haematol, 156(6) (2012) 744-756.
[6] van Imhoff GW, Appel IM, Veeger NJ, Kluin PM, Kluin-Nelemans JC., Gender- and age-related differences in Burkitt lymphoma epidemiological and clinical data from the Netherlands, Eur J Cancer, 40(18) (2004) 2781-2787.
[7] Mead GM, Sydes MR, Walewski J, et al., An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: Results of United Kingdom Lymphoma Group LY06 study, Ann Oncol, 13(8) (2002) 1264.
[8] Hoelzer D, et al., Improved outcomes of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: A report of a large prospective multicenter trial. Blood, The Journal of the American Society of Hematology, 124(26)(2014) 3870-3879.
[9] Jacobson C, LaCasce A., How I treat Burkitt lymphoma in adults. Blood, The Journal of the American Society of Hematology, 124(19)(2014) 2913-2920.
[10] Ribera JM, Garcia O, Grande C, et al., Dose-intensive chemotherapy including rituximab in Burkitt’s leukemia or lymphoma regardless of human immunodeficiency virus infection status: Final results of a phase 2 study (Burkimab). Cancer, 119(9) (2013) 1660-1668.
[11] Casulo C, Friedberg J., Treating Burkitt lymphoma in adults. Current Hematologic Malignancy Reports, 10(3)(2015) 266-271. doi:10.1007/s11899-015-0263-4.
[12] Dunleavy K, Pittaluga S, Shovlin M, et al., Low-intensity therapy in adults with Burkitt’s lymphoma. N Engl J Med., 369(203) 1915-25.
[13] Magrath, I, Adde M, Shad A, et al., Adults and children with small non-cleaved-cell lymphoma have similar excellent outcomes when treated with the same chemotherapy regimen, J Clin Oncol Offic J Am Soc Clin Oncol. 14 (1996) 925-34.
[14] Thomas DA, Faderl S, O’Brien S, et al., Chemoimmunotherapy with hyper-CVAD plus rituximab to treat adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer. 106 (2006) 1569-80.
[15] Salzburg J, et al., Prevalence, clinical patterns, and CNS involvement outcomes in childhood and adolescent non-Hodgkin's lymphoma differ by non-Hodgkin's lymphoma
subtype: A Berlin-Frankfurt-Munster Group Report, Journal of Clinical Oncology, 25(25) (2007) 3915-3922.
[16] Cairo MS, Gerrard M, Sposto R, et al., Results of a randomized international study of high‐risk central nervous system B non‐Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents, Blood, 109(2007) 2736-2743.
[17] Song JY, Venkataraman G, Fedoriw Y, et al. Burkitt leukemia limited to the bone marrow has a better prognosis than Burkitt lymphoma with bone marrow involvement in adults. Leukemia & Lymphoma, 57(4) (2016) 866-871. doi:10.3109/10428194.2015.1085529.
[18] Alshaya, Abdulrahman K, et al., The common complications and comorbidities among Saudi diabetic patients in northern Saudi Arabia, Open Journal of Endocrine and Metabolic Diseases, 7(7) (2017) 151.
[19] Perry, Anamarija M, et al., B‐cell lymphoma, unclassifiable, with features intermediate between diffuse large B‐cell lymphoma and Burkitt lymphoma: A study of 39 cases, British Journal of Haematology, 162(1)(2013) 40-49.